Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Evofem biosciences - The Real Truth

She spent a decade trying to build better women's health care—now her startup is on the brink of failure

Evofem Biosciences CEO Saundra Pelletier has spent a decade trying to steer her startup through a litany of business challenges.

‘Anything to survive’: How one leader is pushing ahead

‘Anything to survive’: How one leader is pushing ahead

The CEO of Evofem Biosciences is managing through a crushing debt load, Nasdaq delisting, and sweeping layoffs.

U.S. women need better birth control. So why is this contraceptive company 'on life support?'

U.S. women need better birth control. So why is this contraceptive company 'on life support?'

Evofem Biosciences has prescribed its nonhormonal contraceptive to more than 100,000 women, but is still on the brink of collapse.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Birth control fail: Why American women can’t have better contraceptives in 2023

The rocky history of Evofem and Phexxi illuminates how big insurers and drugmakers are stifling innovation in women’s health.

12 Health Care Stocks Moving In Friday's Intraday Session

Why Evofem Biosciences Stock Is Surging Today

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading higher Tuesday after the company announced an agreement with a pharmacy benefit manager.

12 Health Care Stocks Moving In Monday's After-Market Session

inkl

Read news from The Economist, FT, and more,
with one subscription

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

Why Evofem Biosciences Shares Are Getting Hammered Today

Why Evofem Biosciences Shares Are Getting Hammered Today

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly $26.6 million public offering.

Evofem Biosciences: Q4 Earnings Insights

Evofem Biosciences: Q4 Earnings Insights

Evofem Biosciences (NASDAQ:EVFM) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

1

Organisations

Paramount Global

Cantor Fitzgerald

Rivian Automotive

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

364,958 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play